{"filings":[{"id":610361,"accession_number":"0001493152-26-025037","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2026-05-22T20:30:23+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.","Each unit includes one ADS (or pre-funded warrant) plus Series H/I/J warrants exercisable at $3.74 per ADS.","Warrants require shareholder approval; pre-funded warrants exercisable immediately.","Net proceeds for working capital and general corporate purposes; Paulson Investment paid 2% cash fee plus 117,647 ADSs.","Offering exempt from registration under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105256,"accession_number":"0001493152-26-010602","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.","No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.","Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.","Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105255,"accession_number":"0001493152-26-008570","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Akari shareholders approve warrant exercises and share issuances at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.","Proposals covered up to ~10M ADSs from Series G/Placement Agent warrants and ~19M ADSs from Pre-Funded/Note Exchange warrants.","All five resolutions passed with over 99% of votes cast in favor; abstentions negligible.","Meeting held March 2, 2026; matters related to capital raises and note exchanges from Dec 2025 and Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121514,"accession_number":"0001493152-25-028075","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","3.02","1.02","7.01","9.01"],"status":"ready","headline":"Akari raises ~$5M in equity; exchanges $4M notes for warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from 10,043,774 ADSs at $0.3883/unit plus pre-funded warrants to insiders for $1M+.","Non-cash reduction of ~$4M in 2026 Notes via exchange for pre-funded warrants and Note Exchange Warrants.","Warrants exercisable after shareholder approval; Series G exercise price $0.3883, 5-year term.","Ladenburg Thalmann acts as placement agent; 8.0% fee, 0.5% mgmt fee, and 504,300 placement agent warrants.","Net proceeds for R&D and working capital; offering closed Dec. 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121513,"accession_number":"0001493152-25-027969","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Akari shareholders approve share sub-division, warrant exercise, and new articles","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved exercisability of warrants issued in October 2025 offering under Nasdaq Listing Rule 5635(d).","Approved sub-division and re-designation of ordinary shares into 1 ordinary share (0.000000005 GBP) and 19,999 deferred shares.","Authorised directors to allot shares up to nominal amount of USD 3,000, expiring June 30, 2030.","Approved a share buyback contract for all deferred shares and adoption of new articles of association.","Special resolution passed to allot equity securities for cash without pre-emption rights, effective for five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121512,"accession_number":"0001493152-25-026533","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akari Therapeutics furnishes investor presentation for conferences","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 on December 8, 2025.","Presentation intended for use at conferences and meetings by company officers.","No specific financial or pipeline details disclosed in the filing body.","Filing signed by President and CEO Abizer Gaslightwala."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121511,"accession_number":"0001493152-25-025177","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Akari Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Akari on Nov 24, 2025 that ADS closing bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until May 25, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured by May 25, 2026, Akari may be eligible for an additional 180-day period if other listing standards are met.","Failure to regain compliance could result in delisting of ADSs from Nasdaq Capital Market.","Akari may consider an ADS ratio change to address the bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121510,"accession_number":"0001493152-25-019112","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Akari Therapeutics appoints Kameel Farag as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.","Compensation: $18,000/month cash + $12,000 in RSUs for Oct-Dec 2025; increases in Jan-Feb 2026.","Consultant also entitled to 1.0% of capital raise proceeds up to $200,000 cap (0.5% after term).","Consulting agreement runs through February 16, 2026, with possible month-to-month extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121509,"accession_number":"0001493152-25-018269","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Issued 3,125,000 ADSs (each representing 2,000 ordinary shares) and Series E/F warrants to purchase up to 3,125,000 ADSs each, all at $0.80 per unit.","Gross proceeds expected ~$2.5M; closing on or about Oct 16, 2025.","Warrants exercisable at $0.98 per ADS upon shareholder approval; 5-year term for Series E, 30-month for Series F.","Net proceeds for working capital, general corporate purposes, and R&D on novel ADC payload.","Placement agent Ladenburg Thalmann receives 7.2% fee plus warrants for 125,000 ADSs at $1.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121508,"accession_number":"0001493152-25-018091","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akari Therapeutics raises $2.5M in registered direct offering and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2.5M from sale of 3,125,000 ADSs at $0.80 per ADS; Ladenburg Thalmann as placement agent.","Concurrent private placement: Series E (5-year) and Series F (30-month) warrants to purchase up to 3.125M ADSs each at $0.98 exercise price; exercisable upon shareholder approval.","Proceeds to fund working capital, general corporate purposes, and R&D; includes generating data on ADC payload AKTX-101 for SITC meeting.","Offering expected to close on or about October 16, 2025, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138194,"accession_number":"0001493152-25-016039","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Akari closes final tranche of August 2025 notes offering for $250K purchase price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate purchase price of $3 million for notes with 20% original issuance discount.","Total principal amount issued approximately $3.8 million across all tranches.","Final tranche: $312,500 principal issued for $250,000 purchase price.","Notes are unsecured promissory notes issued under note purchase agreements dated August 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138193,"accession_number":"0001493152-25-014962","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Akari Therapeutics extends April 2023 notes to Aug 2026, closes $500k tranche, reveals PH1 ADC data","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["April 2023 notes maturity extended to Aug 31, 2026; conversion/exercise price amended to $0.81/ADS ($0.000405 per ordinary share).","Paid ~$81,700 accrued interest through Sep 30, 2025; default claims released.","Closed second tranche of August 2025 Notes: issued $625k principal for $500k; total $3.5M principal issued.","April 2023 warrants exp. extended to Aug 2030, 342,420 ADSs issuable; Series A warrants exp. extended to Apr 2030 for 4,891,272 ADSs.","Preclinical data: PH1 ADC suppresses AR-V7 in mCRPC model; plans to present at scientific conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138192,"accession_number":"0001641172-25-026032","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.","Pricing options include 97% of lowest price in 2-hour window or 20% discount if price below opening.","CFO Torsten Hombeck resigns effective Oct 10, 2025; will consult through Nov 30 for transition.","Company must file S-1 resale registration within 30 days; Exchange Cap at 19.99% of outstanding shares.","Floor price set at $0.20 per ADS; beneficial ownership limit 4.99% (may increase to 9.99% with notice)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138191,"accession_number":"0001641172-25-025104","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.","Chairman Dr. Huh purchased $1,250,000 principal note for $1,000,000, paying $162,567 cash and cancelling $837,433 Peak Bio loan.","Extended expiration of Series A Warrants on 1,973,211 ADSs by 48 months from original expiry.","Paid Paulson Investment Company a 5% advisory fee ($70K) on ~$1.4M gross cash proceeds.","Notes are unsecured; proceeds used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138190,"accession_number":"0001641172-25-024732","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akari Therapeutics posts updated investor presentation; details not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated corporate presentation as Exhibit 99.1 on Form 8-K.","Presentation will be used in meetings but no specific financial or strategic updates provided.","No new material information available beyond the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138189,"accession_number":"0000950170-25-092350","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Akari shareholder-approved 11B share increase for equity plan and director option grant of 1.35M ADSs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in 2023 Plan share pool by 11,026,000,000 ordinary shares (5,513,000 ADSs) to 19,806,000,000 ordinary shares.","Approved aggregate time-vested option grant of 1,350,000 ADSs (2.7B ordinary shares) to six directors, representing 4.2% of issued share capital.","Re-elected all six director nominees: Hoyoung Huh, Robert Bazemore, James Neal, Sandip Patel, Samir Patel, Abizer Gaslightwala.","Ratified BDO USA as independent auditor for FY2025 and HaysMac as statutory auditor.","Advisory votes on NEO compensation and board remuneration report passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155623,"accession_number":"0000950170-25-072046","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.","Cash $2.6M as of March 31, 2025; March 2025 offering netted $6.0M, $4.0M received in April.","Appointed Mark Kubik as Head of Business Development, Oncology to strengthen ADC expertise.","Expects to present preclinical data for PH1-payload ADC at a scientific conference in H2 2025.","Pipeline lead AKTX-101 (Trop2/PH1 ADC) advancing; out-licensing non-core assets for non-dilutive capital."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155622,"accession_number":"0000950170-25-054484","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.","Cash $2.6M at Dec 31, 2024; plus $6.6M private placement in March 2025 funds operations into Sep 2025.","Lead ADC AKTX-101 (TROP2 PH1) for solid tumors; seeking licensing/strategic partner.","Abizer Gaslightwala named President and CEO effective April 21, 2025.","Merger with Peak Bio completed Nov 2024; pipeline focused on next-gen bifunctional ADCs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174119,"accession_number":"0000950170-25-042342","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Akari Therapeutics appoints Abizer Gaslightwala President and CEO; Samir Patel steps down effective April 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Abizer Gaslightwala appointed President and CEO effective ~April 21, 2025; prior SVP at Jazz Pharmaceuticals.","Annual base salary $475,000, target cash bonus of 50% base; time-based option for 1,100,000 ADS (4-yr vest).","Performance-based option for 600,000 ADS vests upon: ≥$15M financing or ≥$10M upfront ADC license by Dec 31, 2025.","Samir Patel steps down as CEO effective April 14, 2025, remains on Board; separation terms pending.","New CEO's employment includes non-compete on ADC-focused biopharma for 12 months post-employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174118,"accession_number":"0001193125-25-043544","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.","ADS unit purchase price: $0.87 plus $0.25–$0.3125 premium per tier; warrants exercisable at $0.87.","Series A warrants expire 1 year, Series B warrants expire 5 years from closing.","Chairman Dr. Hoyoung Huh, CEO Dr. Samir Patel, and all board members participating; $1M note terminated.","Proceeds for working capital; resale registration statement to be filed within 60 days of closing (expected March 5)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174117,"accession_number":"0000950170-25-004576","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Akari Therapeutics updates corporate presentation on bi-functional ADC pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated slide deck highlights next-generation precision bi-functional antibody drug conjugate platform.","Presentation dated January 2025 to be used in meetings with investors and potential partners.","No new financial guidance, clinical data, or operational milestones disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191072,"accession_number":"0000950170-24-137922","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.","Abizer Gaslightwala appointed as Class A director effective Dec 16, 2024; term expires at 2025 AGM.","Michael Grissinger resigned from board on Dec 16, 2024; no disagreement with company operations.","Gaslightwala is SVP at Jazz Pharma, previously at Amgen and Pfizer; deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191071,"accession_number":"0000950170-24-136674","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akari Therapeutics appoints Torsten Hombeck as CFO effective Dec 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Torsten Hombeck appointed CFO effective Dec 16, 2024; previously served as CFO from Oct 2019 to June 2024.","Annual base salary of $300,000 with target bonus of up to 100%.","Dr. Hombeck most recently served as CFO at Aspira Women's Health (June 2023–June 2024).","No family relationships or transactions with other directors or officers noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191070,"accession_number":"0000950170-24-135822","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akari Therapeutics: Interim CFO Wendy DiCicco departs; CEO Samir Patel assumes interim PFO/PAO roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy DiCicco's consulting agreement terminated on December 6, 2024, ending her role as Interim CFO, PFO, and PAO.","Samir Patel, Interim CEO, appointed as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.","Board initiated search for a new Chief Financial Officer.","Separation terms for DiCicco are being finalized and will be disclosed in a subsequent filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191069,"accession_number":"0000950170-24-127107","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","2.01","3.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Akari Therapeutics completes merger with Peak Bio, secures $3.2M PIPE and $50M ELOC term sheet","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed; Peak Bio shareholders received 0.2935 Akari ADS per share, representing ~48.4% of combined entity on fully diluted basis.","Private placement of 1,713,402 ADSs+Warrants at $1.70/unit ($2.385 for insiders) for aggregate gross proceeds of $3.2M.","Entered term sheet for up to $50M equity line of credit with White Lion Capital over 3 years, subject to registration statement.","Nasdaq delisting risk resolved; company believes it now meets $2.5M stockholders' equity requirement post-merger.","Board changes: Wa'el Hashad and Donald Williams resigned; Hoyoung Huh (non-executive chairman), James Neal, Sandip Patel appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191068,"accession_number":"0000950170-24-123703","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.","Transaction expected to close on November 13, 2024.","Upon close, Akari expects to remedy Nasdaq shareholder deficiency, removing delisting risk.","All-stock merger structured for ~50/50 ownership between Akari and Peak Bio holders.","Combined entity to operate as Akari Therapeutics, trading as AKTX on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191067,"accession_number":"0000950170-24-112930","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Akari Therapeutics receives Nasdaq delisting notice; plans to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.","Company intends to request hearing by Oct 8, 2024; hearing automatically stays suspension.","Expects to regain compliance upon closing pending merger with Peak Bio, Inc.","No assurance of success; shares at risk of suspension if appeal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207546,"accession_number":"0000950170-24-107824","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.","Post-merger combined entity to focus on Peak Bio's ADC platform and Akari's PAS-nomacopan GA program; HSCT-TMA suspended.","Interim CEO Samir Patel's monthly $50k compensation changed from shares to NQSOs with 2x ADS multiplier.","PAS-nomacopan IND filing for geographic atrophy expected in 2025; preclinical data suggests 3-month+ intravitreal dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207545,"accession_number":"0000950170-24-104428","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"No material event disclosed; 8-K contains only XBRL context references","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing reports Items 8.01 and 9.01 but provides no narrative or financial data.","No press release, earnings, or other material event attached.","Unable to extract any specific facts, numbers, or names from the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207542,"accession_number":"0000950170-24-100211","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K/A","filed_at":"2024-08-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rachelle Jacques stepped down as President and CEO effective May 1, 2024.","Separation agreement on Aug 19, 2024 provides $450K lump sum payment contingent on merger close or by Dec 2, 2024.","Vesting of RSUs representing 276M ordinary shares; forfeiture of RSUs representing 482.25M ordinary shares.","Payment condition tied to anticipated merger with Peak Bio, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207544,"accession_number":"0000950170-24-098535","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.","Merger with Peak Bio remains on track for Q4 2024 closing; combined entity to focus on ADC platform and PAS-nomacopan for GA.","Raised $7.6M in private placement and issued $1M in convertible notes to CEO and Chairman for operating capital.","Reported net loss of $7.6M for Q2 2024 vs $4.0M in Q2 2023; cash at $4.2M at June 30, 2024.","Received positive pre-IND feedback from FDA for PAS-nomacopan in geographic atrophy; IND filing planned for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207543,"accession_number":"0000950170-24-079669","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Initial June 27 meeting lacked quorum; adjourned to June 28.","All nine ordinary resolutions passed, including re-election of five directors.","Ratified BDO USA as independent auditor and Haysmacintyre as statutory auditor.","Non-binding advisory vote favored annual frequency for say-on-pay.","Votes in favor ranged from 5.7B to 6.5B of ~15.8B outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224975,"accession_number":"0000950170-24-069414","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Akari Therapeutics formalizes interim CEO compensation: $50k/month in equity, no cash/benefits/severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.","Compensation entirely equity-based: $50,000/month in fully vested ordinary shares valued at monthly closing price.","No annual bonus, employee benefits, or severance entitlements; at-will independent contractor role.","Company may terminate agreement immediately for any reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224974,"accession_number":"0000950170-24-068304","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Akari closes ~$7.6M private placement of ADSs and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,817,553 ADSs and warrants at $1.885/unit to investors including chairman and interim CEO; 212,201 units to close later.","Warrants exercisable for 3 years at $1.76/ADS; insider warrants at $1.79/ADS.","Paid Paulson Investment Co. 8% cash fee and issued placement agent warrants for 332,380 ADSs at $1.885, 5-year term.","Company to file resale registration statement with SEC by June 28, 2024.","Securities issued under Section 4(a)(2) and Regulation D; accredited investors only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224973,"accession_number":"0000950170-24-060806","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akari Therapeutics Q1 net loss $5.6M; cash $1.3M; merges with Peak Bio, cuts 67% workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 net loss $5.6M vs net income $1.0M in Q1 2023; adjusted net loss $6.2M excluding warrant gains.","Cash $1.3M as of March 31, 2024; issued $1M in unsecured convertible notes from CEO and Chairman.","Entered all-stock merger with Peak Bio, expected close Q3 2024; combined company will trade as AKTX.","Appointed Samir R. Patel as interim CEO; suspended HSCT-TMA program.","Reduced workforce by ~67% as part of restructuring to cut costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224972,"accession_number":"0000950170-24-054726","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.","Expected severance and related costs $3.1–3.2M, including ~$1.6M non-cash equity vesting; costs payable through Q4 2024.","Board member Rachelle Jacques resigned May 7, 2024; board reduced to five members with no disagreement reported.","Reduction is part of restructuring to cut HSCT-TMA operating costs and support long-term strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224971,"accession_number":"0000950170-24-051383","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Akari Therapeutics CEO and COO exit; merger portfolio prioritizes ADC and GA over other programs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rachelle Jacques stepped down as CEO effective May 1; COO Melissa Bradford-Klug terminated without cause same date.","Board member Samir Patel appointed interim CEO; compensated $50k monthly in RSUs.","Interim CFO DiCicco gets $40k/month, 45% bonus, transaction bonus, and 1% RSU grant.","Merger with Peak Bio to focus on ADC platform (TROP-2) and PAS-nomacopan for Geographic Atrophy.","HSCT-TMA program suspended, PHP 303 discontinued; merger expected close Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224970,"accession_number":"0000950170-24-043519","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Akari Therapeutics receives Nasdaq delisting notice for stockholders' equity deficit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit of $229,000 at Dec 31, 2023 violates Nasdaq's $2.5M minimum equity requirement.","Company received delisting notice on April 5, 2024; must submit compliance plan by May 20, 2024.","If Nasdaq accepts plan, extension possible through Oct 2, 2024 to regain compliance.","Failure to regain compliance may result in delisting; company can request hearing to stay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224969,"accession_number":"0000950170-24-038854","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.","Merger as equals with Peak Bio in all-stock transaction; combined pipeline includes ADC, NEI, nomacopan, PAS-nomacopan.","Nomacopan Phase 3 for pediatric HSCT-TMA ongoing: 10 patients treated; orphan drug and rare pediatric disease designations.","R&D expenses $5.5M (down 43% YoY); G&A $11.4M (down 16% YoY); additional capital planned Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244224,"accession_number":"0001104659-24-033087","cik":1541157,"company_name":"Akari Therapeutics Plc","ticker":"AKTX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Akari Therapeutics raises ~$1.615M in private placement of ADSs for working capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing at lower of $1.57 or 0.7× 15-day VWAP, floor $1.12 per ADS, each ADS representing 2,000 ordinary shares.","Private placement expected to close on or about March 21, 2024, subject to customary conditions.","Placement agent Paulson Investment to receive 10% cash fee and warrants exercisable at 125% of offering price for 5 years.","Company agreed to file registration statement for resale of the ADSs by March 31, 2024.","Exchange cap of 1,320,616 ADSs (19.99% of outstanding ordinary shares) unless shareholder approval obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18227558.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}